Northwest Biotherapeutics, Inc.
NWBO
$0.2984
$0.01525.37%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -35.29% | -30.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.29% | -30.00% | |||
| Cost of Revenue | 29.43% | -1.97% | |||
| Gross Profit | -32.41% | 0.13% | |||
| SG&A Expenses | 16.78% | -27.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.57% | -15.67% | |||
| Operating Income | -24.98% | 15.25% | |||
| Income Before Tax | -45.67% | -8.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -45.67% | -8.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.67% | -8.42% | |||
| EBIT | -24.98% | 15.25% | |||
| EBITDA | -25.81% | 15.70% | |||
| EPS Basic | -40.65% | -2.65% | |||
| Normalized Basic EPS | -58.97% | 9.30% | |||
| EPS Diluted | -9.00% | 0.00% | |||
| Normalized Diluted EPS | -58.97% | 9.30% | |||
| Average Basic Shares Outstanding | 3.89% | 3.64% | |||
| Average Diluted Shares Outstanding | 3.89% | 3.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||